Biomaterial Database

Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). 2021

Jesper Jensen, and Massar Omar, and Caroline Kistorp, and Christian Tuxen, and Ida Gustafsson, and Lars Køber, and Finn Gustafsson, and Jens Faber, and Julie L Forman, and Jacob E Møller, and Morten Schou

Department of Cardiology (J.J., M.S.), Herlev and Gentofte University Hospital, Denmark.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D004311	Double-Blind Method	A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.	Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005960	Glucosides	A GLYCOSIDE that is derived from GLUCOSE.	Glucoside
D006333	Heart Failure	A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077203	Sodium-Glucose Transporter 2 Inhibitors	Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS.	Gliflozin,SGLT-2 Inhibitor,SGLT2 Inhibitor,Sodium-Glucose Transporter 2 Inhibitor,Gliflozins,SGLT-2 Inhibitors,SGLT2 Inhibitors,Inhibitor, SGLT-2,Inhibitor, SGLT2,SGLT 2 Inhibitor,SGLT 2 Inhibitors,Sodium Glucose Transporter 2 Inhibitor,Sodium Glucose Transporter 2 Inhibitors
D001559	Benzhydryl Compounds	Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.	Diphenylmethyl Compounds,Compounds, Benzhydryl,Compounds, Diphenylmethyl
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes